Several companies across various sectors on the Wall Street have seen some Seeking Alpha analyst activity, including both ...

Taking to platforms including Reddit and Telegram for guidance, buyers import small quantities, often described as research ...

This week's dividend activity included increased payouts from General Mills (GIS) and Worthington Enterprises (WOR) as well ...

Rezpeg's promising Phase 2b data makes Nektar Therapeutics a strong contender in the AD market. Click here to read an ...

The stock's fall snapped a four-day winning streak.

Though much of the dust has settled around Novo Nordisk and Eli Lilly’s crusade against compounded GLP-1s, the recent ...

In a breakthrough for incretin medicines, China’s National Medical Products Administration (NMPA) has approved Innovent’s ...

There is a bottomless appetite for news about weight-loss drugs. We cannot hear enough about the celebrities, politicians and ...

In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

A federal judge ruled that the government did not violate the law in a dispute with J&J over the 340B drug discount program.

At BIO 2025, pharmaphorum Editor in Chief spoke with Hanadie Yousef, CEO of Juvena Therapeutics, a biotech focused on discovering and developing tissue-restorative biologics for chronic age-related ...

Empagliflozin has kidney protective effects and reduces heart failure outcomes across baseline kidney function among patients with AMI.